LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion
about
PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesisWnt/β-catenin signalling in prostate cancerERG is a critical regulator of Wnt/LEF1 signaling in prostate cancerProstate cancer invasion and metastasis: insights from mining genomic data.Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity.Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment.Knockdown of lymphoid enhancer factor 1 inhibits colon cancer progression in vitro and in vivo.A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.Functional domains of androgen receptor coactivator p44/Mep50/WDR77and its interaction with Smad1Inhibition of androgen receptor and β-catenin activity in prostate cancerLEF1 identifies androgen-independent epithelium in the developing prostate.Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas.Investigation of anti-cancer mechanisms by comparative analysis of naked mole rat and rat.Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion.LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34aLEF1 targeting EMT in prostate cancer invasion is mediated by miR-181a.Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancerIntegrated network model provides new insights into castration-resistant prostate cancerParathyroid hormone-related protein activates Wnt signaling to specify the embryonic mammary mesenchyme.Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer modelsAndrogen regulation of epithelial-mesenchymal transition in prostate tumorigenesisROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion.Nuclear TBLR1 as an ER corepressor promotes cell proliferation, migration and invasion in breast and ovarian cancer.Wnt signaling in castration-resistant prostate cancer: implications for therapy.microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest.Global human tissue profiling and protein network analysis reveals distinct levels of transcriptional germline-specificity and identifies target genes for male infertility.Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasionProgress in the mechanism and drug development of castration-resistant prostate cancer.Paired box 2 upregulates androgen receptor gene expression in androgen-independent prostate cancer.Expression and proliferation-promoting role of lymphoid enhancer-binding factor 1 in human clear cell renal carcinoma.The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.Revisiting the role of Wnt/β-catenin signaling in prostate cancer.A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cellsMicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer.High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia.Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance.
P2860
Q21245704-2045CCB3-1E52-4A2E-9CBD-0E976E2627AEQ28269116-EFE31216-12C6-4A62-BBDB-D5710C409B2FQ28771736-8A8970A5-6E5D-474C-9EC5-418A8CE2B7C3Q30656758-37894A85-2A3C-4E4C-81C5-A6D38D7C74BCQ33760590-6FAB3CD9-60DE-495C-904A-4E305779A7B1Q33850074-9488A007-AECA-4A83-BFC5-3AC6B2DCF475Q34375679-1828552B-A280-4EB2-AD23-198C9FECD517Q34550256-6926A9A1-2BCB-4DF8-9EDB-B0B6A0458F37Q34755605-862C7422-D345-444B-A30E-E9054DC9A10AQ34982553-3BDC3DE6-0577-49C5-B0B8-0487A81275C8Q35001290-9BBD09EE-FFBF-4088-906F-5A873B074E55Q35052894-7C648E19-E9B8-42BC-BDF0-2DB947E8D3AFQ35102038-01DB24EF-4A7E-4E6D-B9A2-136924DB561DQ35385267-35BFA2F1-0C85-495F-A9C6-90B4D798B013Q35623093-AF5FB91F-52E3-481E-BEFD-5BABD5E7F2CEQ35666448-CE50D9D9-C7E9-47C5-8F8B-BE3EBA602707Q35786826-BAEF2421-3272-40AC-88B7-68D906607F62Q36316657-6B4E2D81-D43C-416E-B03F-07974088571EQ36340155-A92DAD69-979F-44B1-B105-F759B8257E1CQ36435777-5723DED8-9268-4291-963D-7195F25A2750Q36827512-A1716023-BECF-4CF9-9BE8-06AB46A45765Q37270422-C605E610-3A42-43F3-ADE9-92BA0C6A8BBDQ37294322-71FC2CE8-66C6-4BB1-ABC4-DB087B7B91E1Q37382556-4D06761A-1967-41B5-953D-DAF042C37481Q38241850-F6CE2B78-5B38-4FAB-991D-4949239D1DBBQ38300511-F7549779-F754-483C-A2CD-229C3D95CFA5Q38322259-5B799564-00B6-4371-AC65-780F63B6918EQ38751649-CB633E3B-34D8-4D76-AB97-66D3DA933F2AQ38826609-BAF9E930-E1C1-464D-92C1-19FA69F7004AQ38965063-9DB59DD7-058F-4430-9B11-DDC2A84E6B6DQ38988373-DA5D49E5-5FCE-467C-8937-301DAE519AE9Q39033044-C64C7B0B-637F-4801-829A-F79E766BD4BDQ39062137-5635AEC6-10EA-4F52-B8EF-BA09E80EC659Q39068468-49A825F7-023C-48F6-8FCB-5AE874C361D9Q39131794-3A5C9990-2306-4C23-AA10-C0F905D3EAC1Q39195814-B40E5A4D-226A-4351-A652-8801252EF2F5Q39236838-1BCBDDEA-50AE-4715-AACB-C83FA0E3A0A9Q39292672-FCE8EED0-3D01-448F-AFA5-3CBC650585E8Q39310339-BA55245E-D348-4C9B-A629-B0E9886D9A8BQ40625323-425BC3E8-7FB5-48B6-9C0F-237DDEA220FB
P2860
LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@ast
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@en
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@en-gb
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@nl
type
label
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@ast
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@en
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@en-gb
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@nl
prefLabel
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@ast
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@en
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@en-gb
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@nl
P2093
P2860
P3181
P1433
P1476
LEF1 in androgen-independent p ...... te cancer growth, and invasion
@en
P2093
Anna Ferrari
Jianjun Wei
Longgui Wang
Miao Zhang
Michael J Garabedian
Robert Reiter
Xiaomei Liu
Xuanyi Zou
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-08-3380
P407
P577
2009-04-15T00:00:00Z